RXi Pharmaceuticals announced Wednesday it is looking at possible merger-and-acquisition options to advance its clinical pipeline.
The Marlborough biotechnology company has contracted with the investment banking firm Griffin Securities to look at merger-and-acquisition options. Following a reverse stock split in 2015, the company’s capital structure has been reset and put it in a position to execute a merger, said Dr. Geert Cauwenbergh, president and chief executive officer of RXi.
“If successful, would be expected to bring substantial synergies to the combined business and significantly advance our clinical pipeline,” Cauwenbergh said.
There is no guarantee of any merger or acquisition activity, but this exploration is part of the company’s growth process, Cauwenbergh said.
